Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-arm Trial Evaluating Safety and Efficacy of Durvalumab in ECOG Performance Status 2-3, Treatment-naive, Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) and High PD-L1 Tumor Expression

NCT04108026 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT04108026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04108026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-arm Trial Evaluating Safety and Efficacy of Durvalumab in ECOG Performance Status 2-3, Treatment-naive, Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) and High PD-L1 Tumor Expression
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Phase 2
Overall status
Completed
Start date
October 14, 2020
Completion date
September 26, 2025
Enrollment
50 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage iv